Диссертация (1140688), страница 14
Текст из файла (страница 14)
// J. Am. Geriatr. Soc. – 2009;57(11):2125-2133.98.Emphysematous pyelonephritis in the setting of diabetes mellitus. /Gupta P., Gupta R., Jandial K., Samotra S., Rana V., Gupta R,. Gupta S.,Singh J. // J. Assoc. Physicians India. - 2011;59:119-20.99.Emphysematouspyelonephritissuccessfullytreatedbyearlyintervention using a renoureteral catheter. /Teruya H., Mouri T., Kagawa H.,Yamamoto T., Higa F., Tateyama M., Fujita J. // J. Infect Chemother 2009;15(3):195-198.100.Epidemiology and risk factors in urolitiasis.
/Bartoletti R., Cai T.,Montdaini N. Melone F. // Urol. Int. – 2007;79:3-7.101.Evaluation of urolithiasis: a link between stone formation and diabetesmellitus? /Zimmerer T., Weiss C., Hammes H.P., Braun C., Hesse A., AlkenP., Knoll T. // Urol. Int. - 2009;82(3):350-355.102.Evan A.P. Physiopathology and etiology of stone formation in thekidney and the urinary tract. / Evan A.P. // Pediatric Nephrology – 2010;5(25):831-841.103.Extended-spectrum beta-lactamase-producing phenotype signifies apoor prognosis for patients with cefpodoxime-resistant Escherichia coli orKlebsiella pneumoniae bacteremia. / Lee C.I., Lee N.Y., Yan J.J., Lee H.C.,105Ko N.Y., Chang C.M., Wu C.J., Chen P.L., Wang L.R., Ko W.C.// JMicrobiol Immunol Infect - 2009;42(4):303-312.104.Frequency, risk factors, and responsible pathogenic microorganisms ofasymptomatic bacteriuria in patientswith type 2 diabetes mellitus.
/ TuranH., Serefhanoglu K., Torun A.N., Kulaksizoglu S., Kulaksizoglu M., PamukB., Arslan H. // Jpn. J. Infect Dis. - 2008;61(3):236-238.105.Genetics of metabolic syndrome. / Joy T., Lahiry P., Pollex R.L.,Hegele R.A. // Current Diabetes Reports – 2008;8(2):141–148.106.GoldfarbD.S.Prospectsfordietarytherapyofrecurrentnephrolithiasis. /Goldfarb D.S. //Adv Chronic Kidney Dis. -2009;16:21–29.107.Guidelines on urological infections.
/ Grabe M., Bjerklund–JohansenТ., Botto Н., Naber К., Bishop М. // 2010: European Association ofUrology.108.Hall P.M. Nephrolithiasis: treatment, causes, and prevention. / HallP.M. //Cleve Clin J Med. - 2009;76:583–91.109.Hamm L.L. Pathophysiology of hypocitraturic nephrolithiasis. /Hamm L.L., Hering-Smith K.S.
// Endocrinol Metab Clin North Am. –2002;12:885-93.110.Hess В. Metabolic syndrome, obesity and kidney stones. / Hess В. //Arab. Journal of Urology -2012;10(3):258–264.111.Increased acid excretion in kidney stone formers with essentialhypertension. / Losito A., Nunzi E.G., Covarelli C., Nunzi E., Ferrara G. //Nephrol Dial Transplant – 2009;1:137-41.112.Increased risk of urinary tract calculi among patients with diabetesmellitus--a population-based cohort study. / Chen H.S., Su L.T., Lin S.Z.,Sung F.C., Ko M.C., Li C.Y. // Urology. - 2012; 79(1):86-92.113.Insulin resistance and low urinary citrate excretion in calcium stoneformers.
/ Cupisti A., Meola M., D'Alessandro C., Bernabini G., Pasquali E.,Carpi A. // Biomed Pharmacother. - 2007. - № 12. - Р.86-90.106114.International clinical practice guidelines for the treatment of acuteuncomplicated cystitis and pyelonephritis in women: A 2010 update by theInfectious Diseases Society of America and the European Society forMicrobiology and Infectious Diseases. / Gupta K., Hooton Т.М., NaberК.G., Wullt B., Colgan R., Miller L.G., Moran G.J., Nicolle L.E., Raz R.,Schaeffer A.J., Soper D.E. // Clin. Infect Dis.
– 2011;52(5): 13–20.115.Intravenous doripenem at 500 milligrams versus levofloxacin at 250milligrams, with an option to switch to oral therapy, for treatment ofcomplicated lower urinary tract infection and pyelonephritis. / Naber, K.G.,Llorens L., Kaniga K., Kotey P., Hedrich D., Redman R. // Antimicrob.Agents Chemother – 2009;53(9):3782–92.116.Is Urolitiasis Associated with Increased Levels of High Sensitivity C-reactive protein and Interleukin-6 I diabetic Patients? / Hasna A., KavithaM., Senthilkumar G.P., Muruganandham K., Zachariah B. // Journal ofClinical and Diagnostic Research – 2015;9(3):132-137.117.Khaled A.A. Type 2 and vascular complications: A pathophysiologicview.
/ Khaled A.A., Sekaran M., Ikram S.I. // J. Biomed. Res. –2010;21(2):147-155.118.Khan S.R. Reactive oxygen species, inflammation and calcium oxalatenephrolithiasis. / Khan S.R. // Translational Andrology and Urology –2014;3(3):256–276.119.Low urine pH: a novel feature of the metabolic syndrome. / MaaloufN.M., Cameron M.A., Moe O.W., Adams-Huet B.,Sakhaee K. // Clin JAm Soc Nephrol – 2007;9: 883-8.120.Lutsey P.L. Dietary intake and the development of the metabolicsyndrome: the atherosclerosis risk in communities study. / Lutsey P.L,Steffen L.M., Stevens J.
// Circulation – 2008;117(6):754–761.121.Manikandan S. Antimicrobial Susceptibility Pattern of Urinary TractInfection Causing Human Pathogenic Bacteria. / Manikandan S.,107Ganesapandian S., Singh M. //Asian Journal of Medical Sciences –2011;3(2):56-60.122.Marien T. Antimicrobial resistance patterns in cases of obstructivepyelonephritis secondary to stones. / Marien T., Mass A.Y., Shah O. //Urology - 2015;85(1):64-72.123.Medical management of kidney stones: AUA guideline. / Pearle M.S.,Goldfarb D.S., Assimos D.G., Curhan G., Denu-Ciocca C.J., Matlaga B.R.,Monga M., Penniston K.L., Preminger G.M., Turk T.M., White J.R.
// J.Urol - 2014;192(2):316-24.124.Medical therapy to facilitate the passage of stones: What is theevidence? / Seitz C., Liatsikos E., Porpiglia F., Tiselius H.G., Zwergel U. //Eur. Urol. -2009;56:455–71.125.Metabolic Evaluation and Recurrence Prevention for Urinary StonePatients: EAU Guidelines. /Skolarikos A., Straub M., Knoll T., Sarica K.,Seitz C., Petřík A., Türk C. // Eur. Urol. - 2015;67(4):750-763.126.Metabolic syndrome and self-reported history of kidney stones: theNational Health and Nutrition Examination Survey (NHANES III) 19881994. / West B., Luke A., Durazo-Arvizu R.A., Cao G., Shoham D., KramerH. // Am. J.
Kidney Dis. – 2008;5:741-747.127.Mohemid M.A. Antibiotic Resistance Pattern of Bacteria Isolatedfrom Patients of Urinary Tract Infections in Iraq. /Mohemid M.A., SalihA.M. // Open Journal of Urology - 2013;3:124-131.128.Obstructive pyelonephritis as a result of urolithiasis in Japan:Diagnosis, treatment and prognosis. / Hamasuna R., Takahashi S., Nagae H.,Kubo T., Yamamoto S., Arakawa S., Matsumoto T. // Int. J. Urol. –2014;16: 12-15.129.Onat A.
Serum Uric Acid Is a Determinant of Metabolic Syndrome ina Population–Based Study. / Onat A., Uyarel H., Hergen G. //Am. J.Hypertens –2006;19(5):1055–1062.108130.Overweight and obesity: risk factors in calcium oxalate stone disease?/Wrobel B.M., Wrobel B., Hormann M., Strohmaier W.L.
// Advances inUrology – 2012;20:438-441.131.Prevalence of kidney stones in the United States. /Scales C.D., SmithA.C., Hanley J.M., Saigal C.S. // Eur. Urol. - 2012;62(1):160-165.132.Pyelonephritis: what are the present day causative organisms andantibiotic susceptibilities? /Prabhu A., Taylor P., Konecny P., Brown M.A. //Nephrology (Carlton) - 2013;18(6):463-7.133.Retrospective analysis of clinical profile, prognostic factors andoutcomes of 19 patients of emphysematous pyelonephritis. / Khaira A.,Gupta A., Rana D.S., Gupta A., Bhalla A., Khullar D. // Int.
Urol. Nephrol 2009;41:959-966.134.Romero V. Kidney stones: a global picture of prevalence, incidence,and associated risk factors. /Romero V., Akpinar H., Assimos D.S. //Reviews in Urology. 2010;12(2-3):86–96.135.Rule A.D. Kidney stones and the risk for chronic kidney disease./Rule A.D., Bergstralh E.J., Melton L.J. // Clin.
J. Am. Soc. Nephrol 2009;4:804–11.136.Sakhaee K. Clinical review. Kidney stones 2012: pathogenesis,diagnosis, and management. / Sakhaee K., Maalouf N.M., Sinnott B.// J.Clin. Endocrinol. Metab. -2012; 6:1847-60.137.Sakhaee K. Metabolic syndrome and uric acid nephrolithiasis./Sakhaee K., Maalouf N.M. // Seminars in Nephrology – 2008;28(2):174–180.138.SakhaeeK.Recentadvancesinthepathophysiologyofnephrolithiasis. / Sakhaee K. // Kidney Int – 2009;(3):585-595.139.SakhaeeK.Recentadvancesinthepathophysiologyofnephrolithiasis. / Sakhaee K.
// Kidney International – 2009;75(6):585–595.109140.Sorensen S.M. The role of imaging of the urinary tract in patients withurosepsis. / Sorensen S.M., Schonheyder H.C., Nielsen H. // InernationalJournal of Infectious Diseases - 2013;17(5):299–303.141.Strohmaier W.L. Overweight, insulin resistance and blood pressure(parameters of the metabolic syndrome) in uric acid urolithiasis. /StrohmaierW.L., Wrobel B.M., Schubert G. // Urological Research – 2012;40(2):171–175.142.Strope S.A. Changes in gender distribution of urinary stone disease./Strope S.A., Wolf J.S., Hollenbeck B.K.
// Urology – 2010;3:543-546.143.The changing pattern of antimicrobial resistance within 42,033Escherichia coli isolates from nosocomial, community and urology patientspecific urinary tract infections, Dublin, 1999-2009. / Cullen I.M.,Manecksha R.P., McCullagh E., Ahmad S., O'Kelly F., Flynn R.J.,McDermott T., Murphy P., Grainger R., Fennell J.P., Thornhill J.A. // BJUInt.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
